Compare SPSC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPSC | DAWN |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2009 | 2021 |
| Metric | SPSC | DAWN |
|---|---|---|
| Price | $55.64 | $21.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $100.89 | $24.43 |
| AVG Volume (30 Days) | 585.4K | ★ 2.9M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.59 | N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $220,566,000.00 | $158,182,000.00 |
| Revenue This Year | $8.85 | $55.03 |
| Revenue Next Year | $7.37 | $28.12 |
| P/E Ratio | $23.74 | ★ N/A |
| Revenue Growth | 14.11 | ★ 20.60 |
| 52 Week Low | $52.56 | $5.64 |
| 52 Week High | $153.16 | $21.47 |
| Indicator | SPSC | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 38.68 | 80.95 |
| Support Level | $52.81 | $10.30 |
| Resistance Level | $64.46 | N/A |
| Average True Range (ATR) | 2.69 | 0.05 |
| MACD | 0.59 | -0.36 |
| Stochastic Oscillator | 30.58 | 77.78 |
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. Its products are; Fulfillment, Analytics, and Other products like Assortment and Community also it provides one-time services such as professional services and testing and certification. The group derives revenue from subscription-based recurring revenue services.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.